Alzheimer's Disease-Related Dementias Summit 2016: National Research Priorities

Overview

Journal Neurology

Specialty Neurology

Date 2017 Nov 10

PMID 29117955

Citations 87

Authors

Roderick A Corriveau

Walter J Koroshetz

Jordan T Gladman

Sophia Jeon

Debra Babcock

David A Bennett

S Thomas Carmichael

Susan L-J Dickinson

Dennis W Dickson

Marian Emr

Howard Fillit

Steven M Greenberg

Michael L Hutton

David S Knopman

Jennifer J Manly

Karen S Marder

Claudia S Moy

Creighton H Phelps

Paul A Scott

William W Seeley

Beth-Anne Sieber

Nina B Silverberg

Margaret L Sutherland

Angela Taylor

Christine L Torborg

Salina P Waddy

Amelie K Gubitz

David M Holtzman

Affiliations

Soon will be listed here.

Abstract

Goal 1 of the National Plan to Address Alzheimer's Disease is to prevent and effectively treat Alzheimer disease and Alzheimer disease-related dementias by 2025. To help inform the research agenda toward achieving this goal, the NIH hosts periodic summits that set and refine relevant research priorities for the subsequent 5 to 10 years. This proceedings article summarizes the 2016 Alzheimer's Disease-Related Dementias Summit, including discussion of scientific progress, challenges, and opportunities in major areas of dementia research, including mixed-etiology dementias, Lewy body dementia, frontotemporal degeneration, vascular contributions to cognitive impairment and dementia, dementia disparities, and dementia nomenclature.

Citing Articles

Group and partnered dance for people living with dementia: an overview of intervention design and measurement considerations.

Jehu D, Bek J, Bennett C, Hackney M Front Psychol. 2025; 16:1500688.

PMID: 39950072 PMC: 11821603. DOI: 10.3389/fpsyg.2025.1500688.

Editorial. : The journal at age 5.

Hainsworth A, Paracampo R, Wallin A Cereb Circ Cogn Behav. 2024; 7:100368.

PMID: 39737420 PMC: 11683948. DOI: 10.1016/j.cccb.2024.100368.

Economic burden and quality of life of patients with dementia in China: a systematic review and meta-analysis.

Xing B, Li H, Hua H, Jiang R BMC Geriatr. 2024; 24(1):789.

PMID: 39342118 PMC: 11437821. DOI: 10.1186/s12877-024-05359-6.

Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States.

Frech F, Li G, Juday T, Ding Y, Mattke S, Khachaturian A J Prev Alzheimers Dis. 2024; 11(4):983-991.

PMID: 39044509 PMC: 11266270. DOI: 10.14283/jpad.2024.68.

Impact of cognitive impairment on driving behaviour and route choices of older drivers: a real-world driving study.

Derafshi R, Babulal G, Bayat S Sci Rep. 2024; 14(1):14174.

PMID: 38898026 PMC: 11187060. DOI: 10.1038/s41598-024-63663-y.

References

Kalaria R . The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging. 2000; 21(2):321-30. DOI: 10.1016/s0197-4580(00)00125-1. View

Schneider J, Arvanitakis Z, Yu L, Boyle P, Leurgans S, Bennett D . Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain. 2012; 135(Pt 10):3005-14. PMC: 3470712. DOI: 10.1093/brain/aws234. View

Montine T, Koroshetz W, Babcock D, Dickson D, Galpern W, Glymour M . Recommendations of the Alzheimer's disease-related dementias conference. Neurology. 2014; 83(9):851-60. PMC: 4155046. DOI: 10.1212/WNL.0000000000000733. View

Ikeda M, Mori E, Kosaka K, Iseki E, Hashimoto M, Matsukawa N . Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study. Dement Geriatr Cogn Disord. 2013; 36(3-4):229-41. DOI: 10.1159/000351672. View

Reiman E, Langbaum J, Fleisher A, Caselli R, Chen K, Ayutyanont N . Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011; 26 Suppl 3:321-9. PMC: 3343739. DOI: 10.3233/JAD-2011-0059. View

Eichler T, Thyrian J, Hertel J, Michalowsky B, Wucherer D, Dreier A . Rates of formal diagnosis of dementia in primary care: The effect of screening. Alzheimers Dement (Amst). 2016; 1(1):87-93. PMC: 4876881. DOI: 10.1016/j.dadm.2014.11.007. View

Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O, Escott-Price V . Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet. 2014; 23(23):6139-46. PMC: 4222357. DOI: 10.1093/hmg/ddu334. View

Jellinger K, Attems J . Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol. 2010; 119(4):421-33. DOI: 10.1007/s00401-010-0654-5. View

McKeith I, Boeve B, Dickson D, Halliday G, Taylor J, Weintraub D . Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89(1):88-100. PMC: 5496518. DOI: 10.1212/WNL.0000000000004058. View

10.

Evans D, Bennett D, Wilson R, Bienias J, Morris M, Scherr P . Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol. 2003; 60(2):185-9. DOI: 10.1001/archneur.60.2.185. View

11.

W Barker W, Luis C, Kashuba A, Luis M, Harwood D, Loewenstein D . Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002; 16(4):203-12. DOI: 10.1097/00002093-200210000-00001. View

12.

Wesnes K, Aarsland D, Ballard C, Londos E . Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2014; 30(1):46-54. DOI: 10.1002/gps.4109. View

13.

Eichler T, Thyrian J, Hertel J, Kohler L, Wucherer D, Dreier A . Rates of formal diagnosis in people screened positive for dementia in primary care: results of the DelpHi-Trial. J Alzheimers Dis. 2014; 42(2):451-8. DOI: 10.3233/JAD-140354. View

14.

Karran E, Hardy J . Antiamyloid therapy for Alzheimer's disease--are we on the right road?. N Engl J Med. 2014; 370(4):377-8. DOI: 10.1056/NEJMe1313943. View

15.

Vann Jones S, OBrien J . The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2013; 44(4):673-83. DOI: 10.1017/S0033291713000494. View

16.

Gardner R, Valcour V, Yaffe K . Dementia in the oldest old: a multi-factorial and growing public health issue. Alzheimers Res Ther. 2013; 5(4):27. PMC: 3706944. DOI: 10.1186/alzrt181. View

17.

Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K . Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. 2015; 7(1):4. PMC: 4338565. DOI: 10.1186/s13195-014-0083-0. View

18.

Jellinger K, Attems J . Neuropathological evaluation of mixed dementia. J Neurol Sci. 2007; 257(1-2):80-7. DOI: 10.1016/j.jns.2007.01.045. View

19.

Mueller C, Ballard C, Corbett A, Aarsland D . The prognosis of dementia with Lewy bodies. Lancet Neurol. 2017; 16(5):390-398. DOI: 10.1016/S1474-4422(17)30074-1. View

20.

Surmeier D, Obeso J, Halliday G . Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017; 18(2):101-113. PMC: 5564322. DOI: 10.1038/nrn.2016.178. View